Compare Nomura Holdings Inc (NMR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Revvity Inc — how do they compare? Nomura Holdings Inc trades at $9.8 (market cap $28.69B), while Revvity Inc trades at $115.76 (market cap $12.94B). The key difference: Nomura Holdings Inc is far larger — about 2.2× Revvity Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| NMR | RVTY | |
|---|---|---|
Market Cap | $28.69B | $12.94B |
Sector | Financials | Technology |
52-Week High | $10.04 | $117.75 |
52-Week Low | $6.73 | $82.26 |
Dividend Yield | 3.3% | 0.24% |
Enterprise Value | — | $15.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.95, up 0.3% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 11.77 and net income margin of 20.4%, supported by record annual profit in 2025. Recent Q2 2026 earnings beat expectations, and revenue growth trends upward, though cash flow from operations remains negative.
Outlook is positive with valuation appeal and earnings momentum, but risks include volatile cash flows, high debt levels, and reliance on wholesale revenue. Analysts are mixed, with 33% buy ratings. The stock presents a value opportunity amid bullish technicals, yet investors should weigh debt concerns against growth prospects.
RVTY trades at $114.66, up 0.37% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 54.98% gross margin and $241.20M net income for 2025, supported by positive news including product launches and raised 2026 guidance. Analyst consensus is a buy with a $120.50 price target, indicating potential upside from current levels.
Outlook remains positive due to consistent earnings outperformance and innovation in diagnostics, but risks include high P/E valuation and competitive pressures. Investors may find opportunity in sustained margin strength and AI integration, though macroeconomic sensitivity warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
